Becton, Dickinson and Company BDX

183.82 4.59 2.56% as of 25 Sep
Market cap
$48.8B
P/E
55.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Becton, Dickinson and Company (BDX) Revenue growth

Becton, Dickinson and Company's revenue growth over the twelve months to 30 June 2026 was 13.1%, up 4.9 percentage points from fiscal 2025 (8.24%). Over the past ten years it has ranged from −7.03% (fiscal 2020) to 32.2% (fiscal 2018); the current reading is higher than 64% of that period. That is above the Medical Instruments & Supplies industry median of 9.20% and above the Healthcare sector median of 8.26%.

Revenue growth, annual

Annual

Period Revenue growth Change (points)
FY2025 8.24% 4.08
FY2024 4.16% 1.50
FY2023 2.66% 4.02
FY2022 −1.36% (20.38)
FY2021 19.0% 26.05
FY2020 −7.03% (15.21)
FY2019 8.18% (23.99)
FY2018 32.2% 35.29
FY2017 −3.12% (24.53)
FY2016 21.4% (0.33)

Quarterly

Period Revenue growth Change (points)
Jun 2026 5.44% 0.22
Mar 2026 5.22% 3.59
Dec 2025 1.63% (35.69)
Sep 2025 37.3% 42.61
42 more quarters

Against its own ten years

Low −7.03% High 32.2%
Ten-year median 8.18%
Current reading's percentile 64

Revenue growth against peers

Company Revenue growth
ISRG Intuitive Surgical, Inc. compare 20.7%
RGEN Repligen Corporation compare 16.5%
BDX Becton, Dickinson and Company 13.1%
WST West Pharmaceutical Services, Inc. compare 12.4%
RMD ResMed Inc. compare 9.85%
ALC Alcon compare 8.34%
BAX Baxter International Inc. compare 5.36%
SOLV Solventum Corporation compare −0.93%
MDLN Medline Inc. compare —
Medical Instruments & Supplies industry median 9.20%
Healthcare sector median 8.26%
Market median 7.41%

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on BDX